Latest News
Artiva Biotherapeutics, Inc.
- ARTV Holds Steady as Artiva Biotherapeutics Edges Up 0.59% to $6.83 - RSI Overbought Alerts
- Artiva Biotherapeutics Announces Multiple AlloNK® Data
- Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating
- Artiva to present AlloNK data at ACR Convergence 2026 By Investing.com
- Artiva plans phase 3 for NK cell therapy in RA
- Artiva Biotherapeutics Highlights Updated AlloNK® Data in
- Artiva Biotherapeutics at Stifel forum: nk cell therapy gains traction
Headlines from the last 30 days, linking to the original publishers. See all market news →